menu
    • menu

    Company profile for ImmuneOnco

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    ImmuneOnco Biopharmaceuticals Inc. is a science-driven biotechnology company specializing in the development of immuno-oncology therapies. ImmuneOnco is among the few global biotech firms adopting a comprehensive approach that harnesses both innate and adaptive immune systems. While current immunotherapies largely focus on the adaptive immune system and face challenges such as limited response rates and drug resistance, our ap...
    ImmuneOnco Biopharmaceuticals Inc. is a science-driven biotechnology company specializing in the development of immuno-oncology therapies. ImmuneOnco is among the few global biotech firms adopting a comprehensive approach that harnesses both innate and adaptive immune systems. While current immunotherapies largely focus on the adaptive immune system and face challenges such as limited response rates and drug resistance, our approach aims to address these limitations by integrating both immune systems

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ImmuneOncoChina Flag
    Country
    Country
    China
    Address
    Address
    Building 15, Lane 1000, Zhangjiang Science City, Pudong New Area, Shanghai
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://cn.immuneonco.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Instil Bio Reveals '2510 Monotherapy Data for 2L+ Squamous NSCLC
    Instil Bio Reveals '2510 Monotherapy Data for 2L+ Squamous NSCLC

    10 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/10/3147631/0/en/Instil-Bio-Announces-ImmuneOnco-s-Presentation-of-2510-Monotherapy-Data-in-Patients-with-2L-Squamous-NSCLC-at-the-2025-World-Conference-on-Lung-Cancer-WCLC.html

    GLOBENEWSWIRE
    10 Sep 2025
    Share Share
    ImmuneOnco Shares Early IMM2510 NSCLC Trial Data in China
    ImmuneOnco Shares Early IMM2510 NSCLC Trial Data in China

    31 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/31/3124761/0/en/ImmuneOnco-Announced-Preliminary-Safety-Efficacy-Data-from-the-Clinical-Trial-Studying-IMM2510-AXN-2510-a-PD-L1xVEGF-Bispecific-Antibody-in-Combination-with-Chemotherapy-in-Front-l.html

    GLOBENEWSWIRE
    31 Jul 2025
    Share Share
    Instil's PD-L1xVEGF Bispecific Shows Promise in China
    Instil's PD-L1xVEGF Bispecific Shows Promise in China

    31 Jul 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/instils-licensed-pd-l1xvegf-bispecific-shows-promise-china-instilling-hope-upcoming-us-test

    FIERCE BIOTECH
    31 Jul 2025
    Share Share
    Instil Bio gets US FDA clearance for AXN-2510 Phase 1 trial
    Instil Bio gets US FDA clearance for AXN-2510 Phase 1 trial

    02 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/02/3109003/0/en/Instil-Bio-Announces-U-S-F-D-A-Clearance-of-Investigational-New-Drug-IND-Application-for-AXN-2510-a-PD-L1xVEGF-Bispecific-Antibody-for-a-Phase-1-Trial-in-Relapsed-Refractory-Solid-.html

    GLOBENEWSWIRE
    02 Jul 2025
    Share Share
    Instil Bio & ImmuneOnco to Host Investor Breakfast at 2025 ASCO
    Instil Bio & ImmuneOnco to Host Investor Breakfast at 2025 ASCO

    23 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/23/3087397/0/en/Instil-Bio-and-ImmuneOnco-to-Host-Investor-and-Analyst-Breakfast-to-Discuss-the-Evolving-PD-L-1xVEGF-Bispecific-Antibody-Landscape-and-Clinical-Trial-Updates-During-the-2025-ASCO-A.html

    GLOBENEWSWIRE
    23 May 2025
    Share Share
    Instil, ImmuneOnco’s NSCLC Trial on Track for Q3 2025 Completion
    Instil, ImmuneOnco’s NSCLC Trial on Track for Q3 2025 Completion

    22 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/22/3086415/0/en/Instil-Bio-and-ImmuneOnco-Announced-the-Phase-2-Trial-in-First-line-NSCLC-of-IMM2510-AXN-2510-2510-a-PD-L1xVEGF-Bispecific-Antibody-in-Combination-with-Chemotherapy-in-China-is-on-.html

    GLOBENEWSWIRE
    22 May 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search